Daniel Mrak retweeted
New insights into T cell - fibroblast interactions and development of synovial pathotypes in #RA patients.
Thanks to all coauthors!
ard.bmj.com/content/early/20…
Daniel Mrak retweeted
Advanced immunophenotyping: A powerful tool for immune profiling, drug screening, and a personalized treatment appr… pubmed.ncbi.nlm.nih.gov/3703…
Daniel Mrak retweeted
In this large-scale cohort (1222 👥) of symptomatic #PAD, no association of ⬆️Lp(a) with 🫀mortality was found over a median observation period of 5 y
Read the study by @daniel_mrak &al👇
atherosclerosis-journal.com/…
#Lpa #Atherosclerosis #CardioTwitter @EASCongress @society_eas
Advantage of mRNA #COVID booster vaccination as compared to vector in non-seroconverted #immunosuppressed patients: new guidance available! Big thanks to all contributors.
nature.com/articles/s41467-0…
Rituximab and 4th COVID-19 vaccination:
Continuation of rituximab impaires "boostability".
Thanks to our fantastic coautors!
#COVID19 #Booster #rituximab
ard.bmj.com/content/early/20…
Daniel Mrak retweeted
Finally out: our randomized controlled trial provides evidence for efficacy of Tocilizumab in PMR
pubmed.ncbi.nlm.nih.gov/3521…
Daniel Mrak retweeted
Check out the latest findings on #COVID19 vaccination & rituximab:
▶️vaccinacion induce antibodies in RTX-treated patients once peripheral B cells at least partially repopulate
▶️specific T cells were detected, independent of humoral immune response
ard.bmj.com/content/early/20…
Daniel Mrak retweeted
Finally out: new evidence for efficacy and safety of a #COVID19 booster vaccination in #Rituximab-treated patients. Thanks to all the authors! @MedUni_Wien @kim3_med @DanielAletaha @leoheinz @AberleJudith
ard.bmj.com/content/early/20…








